Phio Pharmaceuticals Enters Into Purchase Agreement With TRITON Funds; TRITON To Purchase 18.8% Of Phio's Common Shares Yielding Gross Proceeds Of Up To $621,000
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals has entered into a purchase agreement with TRITON Funds, where TRITON will purchase 18.8% of Phio's common shares, yielding gross proceeds of up to $621,000.
May 17, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phio Pharmaceuticals has secured a purchase agreement with TRITON Funds, which will acquire 18.8% of Phio's common shares, providing up to $621,000 in gross proceeds.
The purchase agreement with TRITON Funds is likely to provide a significant capital infusion for Phio Pharmaceuticals, which could be used for further development and operations. This positive financial development is expected to have a favorable impact on PHIO's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100